Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Response Biomedical to secure $5.5 million in financing
Each whole warrant will entitle the holder thereof to purchase one common share of the company at a price of $0.25 per share for a period of 36
Each whole warrant will entitle the holder thereof to purchase one common share of the company at a price of $0.25 per share for a period of 36
The Angio-Seal Evolution device is designed to enable physicians to quickly and effectively seal femoral artery punctures made during minimally invasive catheter-based procedures. Effectively sealing the puncture helps
Mr Lister will serve on the board’s compensation committee and will focus on guiding the company in the commercialization of new molecular assays. Most recently, Mr Lister was
The new divisions include an in vitro diagnostics (IVD) division specifically focused on accelerating AMDL’s market launch for the AMDL-ELISA DR-70 (FDP) cancer test; a cancer therapeutics division
The technology was developed by Michael Czech, professor and chair, program in molecular medicine at the University of Massachusetts Medical School (UMMS) and an RXi founder, and Gary
The product utilizes the company’s proprietary Strattice technology, which is a sterile reconstructive tissue matrix that supports tissue regeneration. The Strattice technology is a porcine-based, acellular dermal matrix
The company believes the positive opinion of the Committee for Orphan Medicinal Products (COMP) will serve as the scientific basis for the European Commission to issue a EU
According to the company, preclinical studies demonstrated that INS-20 and the FDA-approved Neulasta are comparable in both their pharmacological and toxicological profile. Detailed analytical characterization also demonstrated that
In this newly created position, Dr Geehr will be responsible for the commercial, manufacturing and marketing operations of Abraxis. Most recently, Dr Geehr has been serving as president
With this approval, the company expects to begin enrolling patients into its Prospect II study this quarter, with preliminary results anticipated during the second half of 2009. The